Literature DB >> 20019129

Serum glucocorticoids and adiponectin associate with insulin resistance in children born small for gestational age.

S Tenhola1, B Todorova, J Jääskeläinen, O A Jänne, T Raivio, R Voutilainen.   

Abstract

OBJECTIVES: Altered glucocorticoid activity is one possible mechanism linking fetal growth restriction with later insulin resistance (IR) and type 2 diabetes. We aimed to investigate whether serum glucocorticoid parameters are related to IR in children born small for gestational age (SGA).
DESIGN: A total of 110 children (55 age- and gender-matched pairs born SGA or appropriate for gestational age (AGA) in a case-control setting) were studied at the mean age of 12.2 (s.d. 0.2) years.
METHODS: Serum cortisol, corticosteroid-binding globulin (CBG), free cortisol index (FCI=cortisol/CBG), and glucocorticoid bioactivity (GBA, transactivation assay) were analyzed and related to serum adiponectin and insulin-like growth factor-binding protein 1 (IGFBP1) concentrations and homeostasis model assessment for IR (HOMA-IR) and QUICKI indices.
RESULTS: In the pooled study population, GBA correlated well with cortisol and FCI (r=0.681 and 0.586 respectively; P<0.001 for both). Serum cortisol, CBG, FCI, GBA, HOMA-IR, or QUICKI did not differ between the SGA and AGA subjects, but the SGA children had lower body mass index (P=0.005) and waist circumference (WC) (P=0.001). The mean GBA in the highest GBA quartile was higher among the SGA subjects than among the AGA subjects (138.6 vs 96.4 nmol/l cortisol equivalents, P<0.001). In the SGA children, GBA correlated positively with HOMA-IR (r=0.522, P<0.001) and inversely with adiponectin (r=-0.278, P=0.042) (WC/height ratio adjustments), and in logistic regression analysis, higher GBA (odds ratio (OR) 1.3; P=0.013), lower adiponectin (OR 1.4; P=0.038), and lower IGFBP1 (OR 1.9; P=0.010) associated independently with higher HOMA-IR.
CONCLUSIONS: These findings suggest that increased glucocorticoid activity and low serum adiponectin concentrations associate with IR in SGA children.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20019129     DOI: 10.1530/EJE-09-1003

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Birth-weight, insulin levels, and HOMA-IR in newborns at term.

Authors:  Luis E Simental-Mendía; Argelia Castañeda-Chacón; Martha Rodríguez-Morán; Fernando Guerrero-Romero
Journal:  BMC Pediatr       Date:  2012-07-07       Impact factor: 2.125

2.  The long-term impact of intrauterine growth restriction in a diverse U.S. cohort of children: the EPOCH study.

Authors:  Tessa L Crume; Ann Scherzinger; Elizabeth Stamm; Robert McDuffie; Kimberly J Bischoff; Richard F Hamman; Dana Dabelea
Journal:  Obesity (Silver Spring)       Date:  2013-09-17       Impact factor: 5.002

3.  Association of Serum Total Osteocalcin Concentrations With Endogenous Glucocorticoids and Insulin Sensitivity Markers in 12-Year-Old Children: A Cross-Sectional Study.

Authors:  Satu Seppä; Sirpa Tenhola; Raimo Voutilainen
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-19       Impact factor: 5.555

4.  Biochemistry, hormones and adipocytokines in prepubertal children born with IUGR evoke metabolic, hepatic and renal derangements.

Authors:  Elpida J Sidiropoulou; George Paltoglou; George Valsamakis; Alexandra Margeli; Aimilia Mantzou; Ioannis Papassotiriou; Dimitrios Hassiakos; Nicoletta Iacovidou; George Mastorakos
Journal:  Sci Rep       Date:  2018-10-24       Impact factor: 4.379

5.  Distribution of serum adiponectin isoforms in pediatric patients with steroid-sensitive nephrotic syndrome.

Authors:  Tetsuro Tamai; Kaori Kamijo; Yoshifusa Abe; Satoshi Hibino; Shunsuke Sakurai; Shuichiro Watanabe; Yoshitaka Watanabe; Satomi Nimura; Atsutoshi Shiratori; Takaaki Takayanagi; Tsuneki Watanabe; Yuya Nakano; Hirokazu Ikeda; Kazushige Dobashi; Yasuko Nakano; Katsumi Mizuno; Kazuo Itabashi
Journal:  Clin Exp Nephrol       Date:  2021-06-01       Impact factor: 2.801

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.